Pharmacological blockage of LPA receptors with the pan-LPA antagonist BrP-LPA inhibits human breast MDA-MB-231 cancer cell motility in vitro and promotes tumor regression associated with a decrease in blood vessel density surrounding the tumors in a mouse xenograft model, suggesting that LPA signaling may be a potential therapeutic target for patients with breast cancers [3]. Here, LPA is linked to breast carcinoma.